rethinkTHC Search
Menu
Study breakdown

Clinical guidelines for using cannabis in chronic pain management

Clinical Practice GuidelineModerate evidence
The takeaway

Evidence-based clinical practice guidelines found moderate evidence supporting cannabinoid-based medicines for chronic pain, with additional evidence for co-occurring sleep problems, anxiety, and conditions like MS, fibromyalgia, and HIV-related pain.

Chronic pain patients, primary care providers, pain specialists, medical cannabis clinicians

Moderate evidence for chronic pain benefit

What the researchers found

From 70 articles (19 systematic reviews, 51 original studies), research demonstrates moderate benefit of cannabinoid-based medicines for chronic pain. Evidence also supports efficacy for sleep problems, anxiety, appetite suppression, and pain in HIV, MS, fibromyalgia, and arthritis. Patients should be educated on risks, and clinicians should collaborate on dosing and titration.

Why it matters

Healthcare providers consistently report lacking information about cannabis for pain. These guidelines provide an evidence-based framework for clinicians and patients to navigate cannabis use for chronic pain, filling a major clinical knowledge gap.

The numbers in context

70 articles included (19 systematic reviews, 51 original studies). One in five individuals globally live with chronic pain. GRADE system used for evidence rating.

How the study worked

Systematic review following PRISMA guidelines with dual review. 70 articles met inclusion criteria. Clinical recommendations developed using GRADE system to rate strength of recommendations and quality of evidence. PROSPERO registration #135886.

What this study cannot tell us

Based on available evidence which has significant heterogeneity in cannabinoid formulations, doses, and outcomes. Many studies use pharmaceutical cannabinoids rather than whole-plant products. GRADE ratings reflect moderate quality overall. Cannabis product variability makes standardized recommendations difficult.

How to read the evidence

GRADE-rated clinical practice guideline based on systematic review of 70 articles, with moderate overall evidence quality.

When this study was published

2024 clinical practice guidelines based on systematic review

The bigger picture

One in five people globally lives with chronic pain, often co-occurring with sleep problems, anxiety, depression, and substance use disorders. Guidelines that address cannabis for pain alongside these comorbidities reflect the clinical reality of treating the whole patient.

Questions still open

  • How do whole-plant cannabis products compare to pharmaceutical cannabinoids for pain? Can these guidelines reduce opioid prescribing for chronic pain? How should dosing be adjusted for different pain conditions?

Common questions

Do these guidelines recommend cannabis for chronic pain?
They find moderate evidence supporting cannabinoid-based medicines for chronic pain, particularly when co-occurring with sleep problems or anxiety. They emphasize patient education about risks and collaborative dosing with clinicians.
Which pain conditions have the best evidence?
The strongest evidence was for pain associated with HIV, multiple sclerosis, fibromyalgia, and arthritis. There was also evidence for general chronic pain and cancer-related pain.

Read the original research

Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions.

Cannabis and cannabinoid research, 9(2), 669-687

Citation

Bell, Alan D; MacCallum, Caroline; Margolese, Shari; Walsh, Zach; Wright, Patrick; Daeninck, Paul J; Mandarino, Enrico; Lacasse, Gary; Kaur Deol, Jagpaul; de Freitas, Lauren; St Pierre, Michelle; Belle-Isle, Lynne; Gagnon, Marilou; Bevan, Sian; Sanchez, Tatiana; Arlt, Stephanie; Monahan-Ellison, Max; O'Hara, James; Boivin, Michael; Costiniuk, Cecilia. (2024). Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions.. Cannabis and cannabinoid research, 9(2), 669-687. https://doi.org/10.1089/can.2021.0156

Explore the wider topic